Rajan Karnani, MD
Neurology · Apple Valley, CANPI 1720018484
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,457 of the $6,641 with a category attached, or 82.2%. 46 manufacturers reported payments, led by Livanova USA, Inc. at 25.4% of the total. Reporting peaked in 2022 at $2,438 and has fallen 83.1% since, to $411 in 2025.
Across 290 payments — averaging $22.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Livanova USA, Inc.$2K
- AbbVie$913
- Teva Pharmaceuticals USA, Inc.$439
- Amgen$403
- EMD Serono, Inc.$338
- Biogen$338
- plus $3K from 40 others
What the payments were for
- Speaking & faculty fees$150%
- Travel & lodging$1,15617%
- Food & beverage$5,45782%
- Education$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS Therapy$1,579
How this compares
$6,641 in reported general payments places this provider in the 70th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VumerityDiroximel Fumarate | 17 | $170,360 |
| QuliptaAtogepant | 23 | $26,638 |
| Nurtec OdtRimegepant Sulfate | 17 | $20,119 |
| AptiomEslicarbazepine Acetate | 16 | $19,483 |
| NuedextaDextromethorphan Hbr/Quinidine | 12 | $18,232 |
| Levetiracetam | 250 | $8,336 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 291 | $7,525 |
| Primidone | 326 | $6,556 |
| Gabapentin | 501 | $6,167 |
| Lacosamide | 34 | $4,354 |
| Propranolol Hcl ErPropranolol Hcl | 115 | $4,330 |
| Divalproex Sodium ErDivalproex Sodium | 64 | $2,989 |
| Carbamazepine | 44 | $2,519 |
| Topiramate | 203 | $2,410 |
| Dextroamphetamine Sulfate ErDextroamphetamine Sulfate | 11 | $2,111 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenVumerity | $338 | $170,36017 claims |
| AbbVieQulipta | $913 | $26,63823 claims |
| PfizerNurtec Odt | $15 | $20,11917 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $45 | $18,23212 claims |
| Lilly USA, LLCOlanzapine | $15 | $92640 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $31 | $67517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,996 neurology providers in California.
Other neurology in Apple Valley
- Andrew BlumenfeldCarlsbad$4.9M
- Khashayar DashtipourLoma Linda$3.3M
- Regina BerkovichWest Hollywood$3M
- Daniel BandariNewport Beach$2.6M
- Perry ShiehLos Angeles$2.4M
- Sandeep ThakkarIrvine$2M
- David LiebeskindLos Angeles$1.9M
- Jack SchimCarlsbad$1.7M
- Parshaw DorrizMission Viejo$1.5M
- Benjamin FrishbergCarlsbad$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.